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Abstract
Prevention is defi ned as a coordinated set of actions, at the population level or targeted at an 
individual, aimed at eradicating, eliminating or minimizing the impact of cardiovascular diseases 
(CVD) and their related disability. Prevention is effective in reducing the impact of CVD; the 
elimination of health risk behaviours would make it possible to prevent at least 80% of CVD 
and even 40% of cancers, thus providing added value for other chronic diseases.
The importance of CVD prevention remains undisputed and should be delivered at different 
levels: (i) in the general population by promoting healthy lifestyle behaviour and (ii) at the 
individual level, in those at moderate to high risk of CVD or patients with established CVD, by 
tackling an unhealthy lifestyle (e.g. poorquality diet, physical inactivity, smoking) and by reducing 
increased levels of CV risk factors such as increased lipid or blood pressure levels.
Statins have signifi cant effects on mortality as well as most CVD outcome parameters, these 
drugs are the fi rst choice to reduce total CVD risk. Many randomised controlled trials (RCTs) show 
that statins effectively lower atherogenic cholesterol levels and reduce risk for atherosclerotic 
cardiovascular disease (ASCVD). Some investigators speculate that statins have benefi ts 
beyond cholesterol lowering; pleiotropic effects that remain to be proved. 
On account of its high effi cacy, statin therapy is virtually mandatory for most patients with 
established ASCVD (secondary prevention) but for the population as a whole, the greatest 
potential benefi t lies in prevention of ASCVD in the fi rst place (primary prevention). Statin use 
in primary prevention is the subject of greate debate. Some investigator hold that statin are 
needed for most middle-aged and older people; others contend that statin should be restricted 
to those at highest risk for future ASCVD events.
Therefore, physicians must exercise their best clinical judgement and discuss the advantages 
and disadvantages of statin therapy with their patient. Clinicians should understand the evidence 
but individualize decision making to the specifi c patient or situation.
 
